Dr. Meryl Nass, an internist, biological warfare epidemiologist, and anthrax expert, questioned the purpose of the vaccine. She stated individuals exposed to anthrax need immediate treatment, yet the Cyfendus vaccine, meant to be taken after exposure, can take weeks to months to take effect.
“The FDA admits it does not work because you are required to take antibiotics with it—and it is the antibiotics that actually kill anthrax after an acute exposure.”
Since Cyfendus requires antibacterial drugs to be taken in tandem, Nass noted that she could not identify any new health benefit from this vaccine, especially due to the ingredient list.
The vaccine’s insert states that Cyfendus uses aluminum hydroxide and the synthetic DNA ingredient as adjuvants. According to the study, “Emerging Concepts in the Science of Vaccine Adjuvants,” published in the National Library of Medicine, adjuvants are added to vaccines to stimulate the immune system to respond to the vaccines. The study further states adjuvants derived from alum have been in use since the 1920s and “have been incorporated into billions of doses of vaccines and administered to millions of people every year.”
However, peer-reviewed studies also published in the National Library of Medicine show aluminum adjuvants are known neuro toxins associated with adverse effects. Specifically, the 2007 study, “Aluminum Adjuvant Linked to Gulf War Illness Induces Motor Neuron Death in Mice,” states that the aluminum adjuvant is linked to a “spectrum of disorders” known as Gulf War Illness (GWI), which includes fatigue, muscle aches and joint pains, emotional disorders, posttraumatic stress reactions, headaches, and memory loss.”